Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Daina Graybosch is an analyst at Leerink Partners. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/11/2024
Buy Now | Get Alert | ||||||||
---|---|---|---|---|---|---|---|---|---|
05/15/2024 | BOLT | Buy Now | Bolt Biotherapeutics | $0.75 | 33.87% | $3 → $1 | Downgrade | Outperform → Market Perform | Get Alert |
01/31/2024 | TSVT | Buy Now | 2seventy bio | $3.93 | 358.35% | $5 → $18 | Upgrade | Market Perform → Outperform | Get Alert |
10/30/2023 | TSVT | Buy Now | 2seventy bio | $3.93 | — | — | Downgrade | Outperform → Market Perform | Get Alert |
05/12/2023 | BOLT | Buy Now | Bolt Biotherapeutics | $0.75 | 435.48% | → $4 | Upgrade | Market Perform → Outperform | Get Alert |
03/30/2023 | ACLX | Buy Now | Arcellx | $54.13 | -27.95% | $35 → $39 | Maintains | Outperform | Get Alert |
02/24/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.25 | 139.04% | $5 → $3 | Maintains | Market Perform | Get Alert |
02/03/2023 | MRK | Buy Now | Merck & Co | $130.93 | -6.82% | $120 → $122 | Maintains | Outperform | Get Alert |
01/23/2023 | MRK | Buy Now | Merck & Co | $130.93 | -8.35% | $112 → $120 | Maintains | Outperform | Get Alert |
01/10/2023 | TSVT | Buy Now | 2seventy bio | $3.93 | 765.78% | $41 → $34 | Maintains | Outperform | Get Alert |
01/06/2023 | IPSC | Buy Now | Century Therapeutics | $3.43 | 308.16% | $20 → $14 | Maintains | Outperform | Get Alert |
01/06/2023 | FATE | Buy Now | Fate Therapeutics | $3.86 | 159.07% | $62 → $10 | Maintains | Outperform | Get Alert |
12/13/2022 | FATE | Buy Now | Fate Therapeutics | $3.86 | 1506.22% | $64 → $62 | Maintains | Outperform | Get Alert |
12/12/2022 | AFMD | Buy Now | Affimed | $6.41 | -6.4% | $100 → $60 | Maintains | Outperform | Get Alert |
11/15/2022 | IPHA | Buy Now | Innate Pharma | $2.60 | 246.15% | $10 → $9 | Maintains | Outperform | Get Alert |
11/08/2022 | TSVT | Buy Now | 2seventy bio | $3.93 | 944.03% | $42 → $41 | Maintains | Outperform | Get Alert |
11/03/2022 | RCUS | Buy Now | Arcus Biosciences | $16.30 | 133.13% | $40 → $38 | Maintains | Outperform | Get Alert |
09/30/2022 | MRK | Buy Now | Merck & Co | $130.93 | -15.99% | $109 → $110 | Maintains | Outperform | Get Alert |
09/27/2022 | LVTX | Buy Now | LAVA Therapeutics | $2.44 | 1047.54% | $25 → $28 | Maintains | Outperform | Get Alert |
09/12/2022 | MRK | Buy Now | Merck & Co | $130.93 | -16.75% | $105 → $109 | Maintains | Outperform | Get Alert |
08/29/2022 | MOLN | Buy Now | Molecular Partners | $4.89 | 63.6% | $30 → $8 | Downgrade | Outperform → Market Perform | Get Alert |
08/11/2022 | BOLT | Buy Now | Bolt Biotherapeutics | $0.75 | 435.48% | $8 → $4 | Downgrade | Outperform → Market Perform | Get Alert |
08/04/2022 | RCUS | Buy Now | Arcus Biosciences | $16.30 | 200.61% | $66 → $49 | Maintains | Outperform | Get Alert |
08/02/2022 | IPHA | Buy Now | Innate Pharma | $2.60 | 284.62% | $11 → $10 | Maintains | Outperform | Get Alert |
07/29/2022 | MRK | Buy Now | Merck & Co | $130.93 | -19.8% | $104 → $105 | Maintains | Outperform | Get Alert |
07/29/2022 | BNTX | Buy Now | BioNTech | $97.00 | 130.93% | $223 → $224 | Maintains | Outperform | Get Alert |
07/18/2022 | NKTX | Buy Now | Nkarta | $6.57 | 356.62% | → $30 | Initiates | → Outperform | Get Alert |
07/13/2022 | BNTX | Buy Now | BioNTech | $97.00 | 129.9% | $253 → $223 | Upgrade | Market Perform → Outperform | Get Alert |
06/24/2022 | FSTX | Buy Now | F-star Therapeutics | — | — | $21 → $7 | Downgrade | Outperform → Market Perform | Get Alert |
06/23/2022 | AFMD | Buy Now | Affimed | $6.41 | 40.41% | $100 → $90 | Maintains | Outperform | Get Alert |
06/23/2022 | ACLX | Buy Now | Arcellx | $54.13 | -29.8% | $47 → $38 | Maintains | Outperform | Get Alert |